Have you heard? On August 22, Mahana Therapeutics announced a distribution and marketing partnership with Bayer’s consumer health division. This partnership unites Mahana’s proficiency in digital therapeutic advancement with Bayer’s commitment to empowering individuals through cutting-edge digital solutions, all aimed at enabling greater personal health control. The full press release is linked below.
In light of this, we’re bringing you this replay episode with Simon Levy, CEO and Co-founder, and Ann Montgomery, Chief Product Officer at Mahana.
In their own words, Mahana develops digital treatments for people living with chronic health conditions, and their first treatment, Mahana for IBS, is now available as an FDA-cleared app.

In this episode, we cover:

The founding story and funding journey of Mahana

Complexities of the end to end patient experience

The freemium model and how that translates into a PDT

Evidence generation and FDA clearance process

Scaling plans for PDTs


Guest Links and Resources:

Press Release about the Mahana and Bayer partnership

Connect with Simon Levy on LinkedIn


Connect with Ann Montgomery on LinkedIn


Visit Mahana.com



Host Links:

Connect with Eugene Borukhovich: Twitter | LinkedIn


Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn


Connect with YourCoach.health: Website | Twitter


Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App


HealthXL: Website | Twitter | Join an Event




Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma

Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram